In addition, CRC with wild-type RAS is not always sensitive to anti-EGFR antibodies, while BRAF-mutant CRC has a poor prognosis, as it is associated with lower chemotherapy sensitivity and with clinical situations particularly affecting patient’s performance status [8,9]. This evidence concerns the gene EGFR and colorectal carcinoma.